Skip to main content
OpenTrials
Completed

NCT Number: NCT05939479

Antistaphylococcal Betalactam and Emergence of Resistance

Antistaphylococcal penicillins are recommanded as first-line agent in methicillin-suceptible Staphylococcus aureus bacteraemia. Several studies in progress are investigating the efficacy and safety of cefazolin compared with antistaphylococcal penicillins. Cefazolin has broader spectrum than antistaphylococcal penicillins. The hypothesis of this project is that cefazoline could be responsible for a higher rate of bacterial resistance. The aim is to study the association between the emergence of bacterial resistance and the consumption of cefazolin and antistaphylococcal penicillins.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Bacterial Resistance Methicillin-Sensitive Staphylococcus Aureus Infection

Sex eligibility

All sexes

Study type

Observational

Primary location

Lefevre

Nancy, Lorraine, 54500, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

French hospitals which have collected their consumption and resistance data on the French national database named CONSORES (From 2019 to 2022)

Exclusion criteria

  • None

Treatment and study plan

Primary outcomes

  1. Association between the cefazolin/antistaphylococcal penicillins consumptions and the resistant bacteria emergence

    Time frame: Between the first january 2018 and the 31st december 2022

    The total consumption of antibiotics (expressed as number of Defined Daily Doses (DDD) per 1000 inhabitants per day) will be correlate with the resistant bacteria emergence (only incidence for each bacterial strain)

Secondary outcomes

  1. Factors associated with the emergence of resistant bacteria

    Time frame: Between the first january 2018 and the 31st december 2022

    Factors associated with the emergence of resistant bacteria will be described by a Cox model: hospital size (number of beds), location in France, activities (intensive care, surgery, etc.), type of antibiotics and intensity of consumption expressed in number of defined daily doses (DDD).

  2. Factors associated with the consumption of antibiotics

    Time frame: Between the first january 2018 and the 31st december 2022

    Factors associated with the emergence of resistant bacteria will be described by a Cox model: hospital size (number of beds), location in France, activities (intensive care, surgery, etc.) and type of bacterial strain indentified (resistant or not).

  3. Evolution of resistance in French hospitals

    Time frame: Between the first january 2018 and the 31st december 2022

    For each year, bacterial resistance will be described, in France and in each hospital, in the form of a quantitative variable: number of resistant bacterial strains isolated for each year (number of resistant strains / total number of strains).

  4. Evolution of antibiotics consumption in French hospitals

    Time frame: Between the first january 2018 and the 31st december 2022

    For each year, antibiotic consumption will be described, in France and in each hospital, in the form of a quantitative variable (expressed as number of Defined Daily Doses (DDD) per 1000 inhabitants per day)

Sponsors and collaborators

Lead sponsor

Central Hospital, Nancy, France

Other

Registry information

Official study title

Impact of Antistaphylococcal Penicillins and Cefazolin on the Emergence of Resistance in French Hospitals

Acronym: CePasR

Important dates

Study start
2018
Primary completion
2023
Study completion
2023
First posted
Jul 11, 2023
Registry last updated
Aug 8, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.